AbSci Appoints Andrew J.S. Jones, D. Phil to Scientific Advisory Board
“It is rejuvenating to be working with a young and energetic company like AbSci. Their exciting technology not only has dramatic development, yield and production speed advantages for manufacture of complex biopharmaceuticals,” – Andrew J.S. Jones, D. Phil
AbSci to attend BIO-Europe 2018, 5th – 7th November 2018, in Copenhagen, Denmark
AbSci to attend the Bio-Europe 2018 conference in Copenhagen, Denmark from 5th – 7th November 2018 If you would like to meet with an AbSci Business Development professional, please email us at partnering at abscibio.com
AbSci Named Washington 100 Best Companies to Work For
We’re excited to announce that AbSci made Seattle Business Magazine’s list of Washington’s 100 Best Companies to Work For! This year marks the 29th annual release of the Seattle Business Magazine’s 100 Best Companies to Work For list, as they look for the top...
AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression Platform
The Series C Round led by Asahi Glass Co., Ltd. “AGC” includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.
Sean McClain of AbSci Entrepreneur Of The Year® 2018 Award Finalist in the Pacific Northwest
EY Announces Sean McClain of AbSci Entrepreneur Of The Year® 2018 Award Finalist in the Pacific Northwest region Vancouver, Washington May 7th, 2018 – EY announced that Founder and CEO Sean McClain of AbSci is a finalist for the Entrepreneur Of The Year® 2018 Award in...
AbSci hopes to make E. Coli great again through engineered expression system
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems …
AbSci Adds Protein Characterization Expert, Alan Herman, PhD to Scientific Advisory Board
“There’s an electricity of discovery here like Genentech and Amgen,” said Dr. Herman. “AbSci’s ability to fold proteins is an innovative art form. This technology enables more efficient manufacturing, which will bring down the price of drugs.”
AbSci Appoints William F. Bennett, PhD to Scientific Advisory Board
“The culture here reminds me of Genentech in the early days. It’s an honor to join the team as a Scientific Advisor,” said Dr. Bennett. “AbSci’s technology is a quantum improvement in bacterial expression systems.”
AbSci at 36th JP Morgan Conference January 8th – 11th.
AbSci at 36th JP Morgan Conference January 8th – 11th. The team is fully booked out for the remainder of JPM – Contact Kole Krieger to schedule a phone call – kkrieger@abscibio.com
AbSci Appoints Fred Larimore, PhD to Scientific Advisory Board
AbSci announced today the appointment of Fred Larimore, PhD to AbSci’s Scientific Advisory Board. Dr. Larimore brings over 30 years of experience in biopharmaceutical manufacturing and process development at leading pharmaceutical companies …